Clinical Trials Logo
  1. Home
  2. Nonsmall Cell Lung Cancer
  3. NCT03940846

CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology

Nonsmall Cell Lung Cancer Clinical Trial

Official title:
CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology

Clinical Trial Summary

Lung cancer remains the leading cause of cancer related mortality worldwide, with more than 1.5 million related deaths annually. Lung cancer is divided into two main groups: Small Cell Lung Carcinoma (SCLC) and Non-Small Cell Lung Carcinoma (NSCLC), with prevalence of ~20% and 80% respectively. NSCLC is further subdivided into adenocarcinoma (the most common), squamous cell carcinoma (SCC), and large cell carcinoma. Furthermore, each subtype is likely to have specific mutations, which could be targeted for treatment.

Medical imaging and radiomics feature extraction represent a candidate alternative to conventional tissue biopsy, a theory that is investigated in this study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03940846
Study type Observational
Source Maastricht University
Contact
Status Active, not recruiting
Phase
Start date March 1, 2019
Completion date January 31, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06147570 - A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01312337 - Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT05860582 - A Study of [14C]GB491 in Male Healthy Subjects Phase 1
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT02562027 - SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer N/A
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Active, not recruiting NCT02954523 - Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Terminated NCT03998189 - Metabolic and Microbial Profiling of Lung Cancer N/A
Not yet recruiting NCT03258671 - IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer N/A
Recruiting NCT03838588 - The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Active, not recruiting NCT04984811 - NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Phase 2
Recruiting NCT05688280 - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS Phase 1/Phase 2
Recruiting NCT02951611 - Effects of Acupuncture Stimulation on Systemic Inflammation N/A
Recruiting NCT02974933 - Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT02980536 - cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China
Completed NCT02972216 - Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Phase 4
Recruiting NCT02905591 - A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC Phase 2
Recruiting NCT05873439 - Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC Early Phase 1
Active, not recruiting NCT02981108 - A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC Phase 1/Phase 2
Active, not recruiting NCT02299141 - Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Phase 2